

Information Governance

25 June 2021

Our Ref: RFI 38606

Dear

Freedom of Information Act 2000

RE: Information relating to biologic and biosimilar products within Rheumatology.

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to biologic and biosimilar products within Rheumatology which you requested on 15 April 2021.

Please accept my apologies for the delay in responding to your correspondence as the Information Governance Department is dealing with a large number of requests for information, including a backlog of requests as a result of the Covid-19 pandemic which had a major impact across services.

A response to each of the questions raised has been provided by the Hospital Service Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Joyce Batch
Information Governance Assistant

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Response derived from Pharmacy records inserted in table below. Figures relate to 3 month period from 01/03/2021 to 31/05/2021.

Drug Name	Patients Treated
Abatacept [Orencia]	13
Adalimumab [Humira]	88
Adalimumab [Amgevita]	>5*
Adalimumab [Hymiroz]	0
Adalimumab [Imraldi]	182
Adalimumab [Idacio]	0
Apremilast [Otezla]	>5*
Baricitinib [Olumiant]	42
Certolizumab [Cimzia]	>5*
Etanercept [Enbrel]	50
Etanercept Biosimilars	100
Filgotinib [Jyseleca]	0
Golimumab [Simponi]	69
Infliximab [Remicade]	>5*
Infliximab Biosimilars	>5*
Ixekizumab [Taltz]	>5*
Rituximab [MabThera]	11
Rituximab Biosimilars	15
Sarilumab [Kevzara]	>5*
Secukinumab [Cosentyx]	37
Tocilizumab [Ro Actemra]	27
Tofacitinib [Xeljanz]	8
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	>5*

** You will note that some of the numbers have been masked due to low numbers in a small geographical area.*